請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/18399
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 姜至剛(Chih-Kang Chiang) | |
dc.contributor.author | Da-Gong Huang | en |
dc.contributor.author | 黃大恭 | zh_TW |
dc.date.accessioned | 2021-06-08T01:03:17Z | - |
dc.date.copyright | 2020-08-27 | |
dc.date.issued | 2020 | |
dc.date.submitted | 2020-08-18 | |
dc.identifier.citation | 1. Bhargava, P. and R.G. Schnellmann, Mitochondrial energetics in the kidney. Nature Reviews Nephrology, 2017. 13(10): p. 629-646. 2. Luyckx, V.A., M. Tonelli, and J.W. Stanifer, The global burden of kidney disease and the sustainable development goals. Bulletin of the World Health Organization, 2018. 96(6): p. 414-422. 3. James, M.T., et al., Long-term outcomes of acute kidney injury and strategies for improved care. Nature Reviews Nephrology, 2020: p. 1-13. 4. Lameire, N.H., et al., Acute kidney injury: an increasing global concern. The Lancet, 2013. 382(9887): p. 170-179. 5. Basile, D.P., M.D. Anderson, and T.A. Sutton, Pathophysiology of acute kidney injury. Comprehensive Physiology, 2011. 2(2): p. 1303-1353. 6. Urden, L.D., K.M. Stacy, and M.E. Lough, Critical Care Nursing-E-Book: Diagnosis and Management. 2017: Elsevier Health Sciences. 7. Singh, A.K., et al., Epidemiology and risk factors of chronic kidney disease in India–results from the SEEK (Screening and Early Evaluation of Kidney Disease) study. BMC nephrology, 2013. 14(1): 114. 8. Bikbov, B., et al., Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet, 2020. 395(10225): p. 709-733. 9. Romagnani, P., et al., Chronic kidney disease. Nature Reviews Disease Primers, 2017. 3(1): p. 1-24. 10. Eknoyan, G., et al., KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int, 2013. 3(1): p. 5-14. 11. Abbasi, M.A., G.M. Chertow, and Y.N. Hall, End-stage renal disease. BMJ clinical evidence, 2010. 12. Schena, F.P., Epidemiology of end-stage renal disease: International comparisons of renal replacement therapy. Kidney international, 2000. 57: S39-S45. 13. Mikolasevic, I., et al., Dyslipidemia in patients with chronic kidney disease: etiology and management. International journal of nephrology and renovascular disease, 2017. 10: p. 35-45. 14. Staples, A.O., et al., Association between clinical risk factors and progression of chronic kidney disease in children. Clinical Journal of the American Society of Nephrology, 2010. 5(12): p. 2172-2179. 15. Ishani, A., et al., Acute kidney injury increases risk of ESRD among elderly. Journal of the American Society of Nephrology, 2009. 20(1): p. 223-228. 16. Chawla, L.S. and P.L. Kimmel, Acute kidney injury and chronic kidney disease: an integrated clinical syndrome. Kidney international, 2012. 82(5): p. 516-524. 17. Ferenbach, D.A. and J.V. Bonventre, Mechanisms of maladaptive repair after AKI leading to accelerated kidney ageing and CKD. Nature Reviews Nephrology, 2015. 11(5): p. 264-276. 18. Hsu, R.K. and C.-y. Hsu. The role of acute kidney injury in chronic kidney disease. in Seminars in nephrology. 2016. Elsevier. 19. Tan, H.L., J.Q. Yap, and Q. Qian, Acute kidney injury: tubular markers and risk for chronic kidney disease and end-stage kidney failure. Blood purification, 2016. 41(1-3): p. 144-150. 20. Akcay, A., Q. Nguyen, and C.L. Edelstein, Mediators of inflammation in acute kidney injury. Mediators of inflammation, 2009. 21. Denic, A., et al., The substantial loss of nephrons in healthy human kidneys with aging. Journal of the American Society of Nephrology, 2017. 28(1): p. 313-320. 22. Canaud, G. and J.V. Bonventre, Cell cycle arrest and the evolution of chronic kidney disease from acute kidney injury. Nephrology Dialysis Transplantation, 2015. 30(4): p. 575-583. 23. Afsar, B., et al., Capillary rarefaction from the kidney point of view. Clinical kidney journal, 2018. 11(3): p. 295-301. 24. Tang, J. and S. Zhuang, Epigenetics in acute kidney injury. Current opinion in nephrology and hypertension, 2015. 24(4): p. 351-358. 25. Maekawa, H. and R. Inagi. Pathophysiological Role of Organelle Stress/Crosstalk in AKI-to-CKD Transition. in Seminars in Nephrology. 2019. Elsevier. 26. de Seigneux S, Martin PY. Preventing the progression of AKI to CKD: the role of mitochondria. Journal of the American Society of Nephrology. 2017;28(5): p. 1327–1329. 27. Lan, R., et al., Mitochondrial pathology and glycolytic shift during proximal tubule atrophy after ischemic AKI. Journal of the American Society of Nephrology, 2016. 27(11): p. 3356-3367. 28. Padanilam, B.J., et al., Defective mitochondrial fatty acid oxidation and lipotoxicity in kidney diseases. Frontiers in Medicine, 2020. 7: 65. 29. Kang, H.M., et al., Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development. Nature medicine, 2015. 21(1): p. 37-46. 30. Simon, N. and A. Hertig, Alteration of fatty acid oxidation in tubular epithelial cells: from acute kidney injury to renal fibrogenesis. Frontiers in medicine, 2015. 2: 52. 31. Detmer, S.A. and D.C. Chan, Functions and dysfunctions of mitochondrial dynamics. Nature reviews Molecular cell biology, 2007. 8(11): p. 870-879. 32. Galvan, D.L., N.H. Green, and F.R. Danesh, The hallmarks of mitochondrial dysfunction in chronic kidney disease. Kidney international, 2017. 92(5): p. 1051-1057. 33. El-Hattab, A.W., et al., Mitochondrial dynamics: Biological roles, molecular machinery, and related diseases. Molecular genetics and metabolism, 2018. 125(4): p. 315-321. 34. Chen, H., et al., Mitofusins Mfn1 and Mfn2 coordinately regulate mitochondrial fusion and are essential for embryonic development. The Journal of cell biology, 2003. 160(2): p. 189-200. 35. Twig, G. and O.S. Shirihai, The interplay between mitochondrial dynamics and mitophagy. Antioxidants redox signaling, 2011. 14(10): p. 1939-1951. 36. El-Hattab, A.W., W.J. Craigen, and F. Scaglia, Mitochondrial DNA maintenance defects. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 2017. 1863(6): p. 1539-1555. 37. Suárez-Rivero, J.M., et al., Mitochondrial dynamics in mitochondrial diseases. Diseases, 2017. 5(1): 1. 38. Palikaras, K. and N. Tavernarakis, Mitochondrial homeostasis: the interplay between mitophagy and mitochondrial biogenesis. Experimental gerontology, 2014. 56: p. 182-188. 39. Austin, S. and J. St-Pierre, PGC1α and mitochondrial metabolism–emerging concepts and relevance in ageing and neurodegenerative disorders. Journal of cell science, 2012. 125(21): p. 4963-4971. 40. Ding, W.-X. and X.-M. Yin, Mitophagy: mechanisms, pathophysiological roles, and analysis. Biological chemistry, 2012. 393(7): p. 547-564. 41. Gatica, D., V. Lahiri, and D.J. Klionsky, Cargo recognition and degradation by selective autophagy. Nature cell biology, 2018. 20(3): p. 233-242. 42. Nguyen, T.N., B.S. Padman, and M. Lazarou, Deciphering the molecular signals of PINK1/Parkin mitophagy. Trends in cell biology, 2016. 26(10): p. 733-744. 43. Moorhead, J., et al., Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. The Lancet, 1982. 320(8311): p. 1309-1311. 44. Portilla, D., et al., Metabolomic study of cisplatin-induced nephrotoxicity. Kidney international, 2006. 69(12): p. 2194-2204. 45. Herman-Edelstein, M., et al., Altered renal lipid metabolism and renal lipid accumulation in human diabetic nephropathy. Journal of lipid research, 2014. 55(3): p. 561-572. 46. Yang, W., et al., Ectopic lipid accumulation: potential role in tubular injury and inflammation in diabetic kidney disease. Clinical Science, 2018. 132(22): p. 2407-2422. 47. Jao, T.-M., et al., ATF6α downregulation of PPARα promotes lipotoxicity-induced tubulointerstitial fibrosis. Kidney international, 2019. 95(3): p. 577-589. 48. Fujimoto, T. and R.G. Parton, Not just fat: the structure and function of the lipid droplet. Cold Spring Harbor perspectives in biology, 2011. 3(3): a004838. 49. Guo, Y., et al., Lipid droplets at a glance. J Cell Sci, 2009. 122(6): p. 749-752. 50. Nishi, H., T. Higashihara, and R. Inagi, Lipotoxicity in Kidney, Heart, and Skeletal Muscle Dysfunction. Nutrients, 2019. 11(7): 1664. 51. Weinberg, J., Lipotoxicity. Kidney international, 2006. 70(9): p. 1560-1566. 52. Bobulescu, I.A., Renal lipid metabolism and lipotoxicity. Current opinion in nephrology and hypertension, 2010. 19(4): p. 393-402. 53. Levi, M., Role of Bile Acid–Regulated Nuclear Receptor FXR and G Protein–Coupled Receptor TGR5 in Regulation of Cardiorenal Syndrome (Cardiovascular Disease and Chronic Kidney Disease). Hypertension, 2016. 67(6): p. 1080-1084. 54. Saponaro, C., et al., The subtle balance between lipolysis and lipogenesis: a critical point in metabolic homeostasis. Nutrients, 2015. 7(11): p. 9453-9474. 55. Dorotea, D., D. Koya, and H. Ha, Recent Insights Into SREBP as a Direct Mediator of Kidney Fibrosis via Lipid-Independent Pathways. Frontiers in Pharmacology, 2020. 11: 265. 56. Ye, J. and R.A. DeBose-Boyd, Regulation of cholesterol and fatty acid synthesis. Cold Spring Harbor perspectives in biology, 2011. 3(7): a004754. 57. Armengol, S., et al., SREBP-2-driven transcriptional activation of human SND1 oncogene. Oncotarget, 2017. 8(64): p. 108181-108194. 58. Sun, L., et al., Role of sterol regulatory element-binding protein 1 in regulation of renal lipid metabolism and glomerulosclerosis in diabetes mellitus. Journal of Biological Chemistry, 2002. 277(21): p. 18919-18927. 59. Mustafa, M., et al., SREBP inhibition ameliorates renal injury after unilateral ureteral obstruction. American Journal of Physiology-Renal Physiology, 2016. 311(3): F614-F625. 60. Kazantzis, M. and A. Stahl, Fatty acid transport proteins, implications in physiology and disease. Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids, 2012. 1821(5): p. 852-857. 61. Mashek, D.G. and R.A. Coleman, Cellular fatty acid uptake: the contribution of metabolism. Current opinion in lipidology, 2006. 17(3): p. 274-278. 62. Su, X. and N.A. Abumrad, Cellular fatty acid uptake: a pathway under construction. Trends in Endocrinology Metabolism, 2009. 20(2): p. 72-77. 63. Silverstein, R.L. and M. Febbraio, CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, and behavior. Science signaling, 2009. 2(72): re3-re3. 64. Park, Y.M., CD36, a scavenger receptor implicated in atherosclerosis. Experimental molecular medicine, 2014. 46(6): e99-e99. 65. Yang, X., et al., CD36 in chronic kidney disease: novel insights and therapeutic opportunities. Nature Reviews Nephrology, 2017. 13(12): p. 769-781. 66. Zhao, L., et al., CD36 and lipid metabolism in the evolution of atherosclerosis. British medical bulletin, 2018. 126(1): p. 101-112. 67. Jung, J.H., et al., Human CD36 overexpression in renal tubules accelerates the progression of renal diseases in a mouse model of folic acid-induced acute kidney injury. Kidney research and clinical practice, 2018. 37(1): p. 30-40. 68. Yokoi, H. and M. Yanagita, Targeting the fatty acid transport protein CD36, a class B scavenger receptor, in the treatment of renal disease. Kidney international, 2016. 89(4): p. 740-742. 69. Okamura, D.M., et al., CD36 regulates oxidative stress and inflammation in hypercholesterolemic CKD. Journal of the American Society of Nephrology, 2009. 20(3): p. 495-505. 70. Houten, S.M., et al., The biochemistry and physiology of mitochondrial fatty acid β-oxidation and its genetic disorders. Annual review of physiology, 2016. 78: p. 23-44. 71. Rinaldo, P., D. Matern, and M.J. Bennett, Fatty acid oxidation disorders. Annual review of physiology, 2002. 64(1): p. 477-502. 72. Houten, S.M. and R.J. Wanders, A general introduction to the biochemistry of mitochondrial fatty acid β-oxidation. Journal of inherited metabolic disease, 2010. 33(5): p. 469-477. 73. Reddy, J.K. and M. Sambasiva Rao, Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. American Journal of Physiology-Gastrointestinal and Liver Physiology, 2006. 290(5): G852-G858. 74. Serra, D., et al., Mitochondrial fatty acid oxidation in obesity. Antioxidants redox signaling, 2013. 19(3): p. 269-284. 75. Carracedo, A., L.C. Cantley, and P.P. Pandolfi, Cancer metabolism: fatty acid oxidation in the limelight. Nature reviews Cancer, 2013. 13(4): p. 227-232. 76. Zhou, D. and Y. Liu, Renal fibrosis in 2015: Understanding the mechanisms of kidney fibrosis. Nature reviews. Nephrology, 2016. 12(2): p. 68-70. 77. Tyagi, S., et al., The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases. Journal of advanced pharmaceutical technology research, 2011. 2(4): p. 236-240. 78. Pawlak, M., P. Lefebvre, and B. Staels, Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. Journal of hepatology, 2015. 62(3): p. 720-733. 79. Szeto, H.H., Pharmacologic approaches to improve mitochondrial function in AKI and CKD. Journal of the American Society of Nephrology, 2017. 28(10): p. 2856-2865. 80. Qu, Q., et al., Fatty acid oxidation and carnitine palmitoyltransferase I: emerging therapeutic targets in cancer. Cell death disease, 2016. 7(5): e2226-e2226. 81. Shekhawat, P., et al., Human placenta metabolizes fatty acids: implications for fetal fatty acid oxidation disorders and maternal liver diseases. American Journal of Physiology-Endocrinology and Metabolism, 2003. 284(6): E1098-E1105. 82. Jang, H.-S., et al., Proximal tubule cyclophilin D regulates fatty acid oxidation in cisplatin-induced acute kidney injury. Kidney International, 2020. 97(2): p. 327-339. 83. Chung, K.W., et al., Impairment of PPARα and the fatty acid oxidation pathway aggravates renal fibrosis during aging. Journal of the American Society of Nephrology, 2018. 29(4): p. 1223-1237. 84. Kostapanos, M.S., M. Florentin, and M.S. Elisaf, Fenofibrate and the kidney: an overview. European journal of clinical investigation, 2013. 43(5): p. 522-531. 85. Li, L., et al., Fenofibrate attenuates tubulointerstitial fibrosis and inflammation through suppression of nuclear factor-κ B and transforming growth factor-β 1/Smad3 in diabetic nephropathy. Experimental Biology and Medicine, 2010. 235(3): p. 383-391. 86. Tanaka, Y., et al., Fenofibrate, a PPARα agonist, has renoprotective effects in mice by enhancing renal lipolysis. Kidney international, 2011. 79(8): p. 871-882. 87. Broeders, N., et al., Fibrate‐induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent? Nephrology Dialysis Transplantation, 2000. 15(12): p. 1993-1999. 88. Emami, F., et al., Fenofibrate-induced renal dysfunction, yes or no? Journal of Research in Medical Sciences, 2020. 25(1): 39. 89. Schwarz, D.S. and M.D. Blower, The endoplasmic reticulum: structure, function and response to cellular signaling. Cellular and Molecular Life Sciences, 2016. 73(1): p. 79-94. 90. Braakman, I. and D.N. Hebert, Protein folding in the endoplasmic reticulum. Cold Spring Harbor perspectives in biology, 2013. 5(5): a013201. 91. Kapoor, A. and A.J. Sanyal, Endoplasmic reticulum stress and the unfolded protein response. Clinics in liver disease, 2009. 13(4): p. 581-590. 92. Inagi, R., Y. Ishimoto, and M. Nangaku, Proteostasis in endoplasmic reticulum—new mechanisms in kidney disease. Nature Reviews Nephrology, 2014. 10(7): p. 369-378. 93. Schröder, M. and R.J. Kaufman, ER stress and the unfolded protein response. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, 2005. 569(1-2): p. 29-63. 94. Wang, M., et al., Role of the unfolded protein response regulator GRP78/BiP in development, cancer, and neurological disorders. Antioxidants redox signaling, 2009. 11(9): p. 2307-2316. 95. Basseri, S. and R.C. Austin, Endoplasmic reticulum stress and lipid metabolism: mechanisms and therapeutic potential. Biochemistry research international, 2012: 841362. 96. Rozpedek, W., et al., The role of the PERK/eIF2α/ATF4/CHOP signaling pathway in tumor progression during endoplasmic reticulum stress. Current molecular medicine, 2016. 16(6): p. 533-544. 97. Pällmann, N., et al., Regulation of the unfolded protein response through ATF4 and FAM129A in prostate cancer. Oncogene, 2019. 38(35): p. 6301-6318. 98. Marciniak, S.J., et al., CHOP induces death by promoting protein synthesis and oxidation in the stressed endoplasmic reticulum. Genes development, 2004. 18(24): p. 3066-3077. 99. Iurlaro, R. and C. Muñoz‐Pinedo, Cell death induced by endoplasmic reticulum stress. The FEBS journal, 2016. 283(14): p. 2640-2652. 100. Wu, R., et al., Involvement of the IRE1α-XBP1 pathway and XBP1s-dependent transcriptional reprogramming in metabolic diseases. DNA and cell biology, 2015. 34(1): p. 6-18. 101. Huang, S., Y. Xing, and Y. Liu, Emerging roles for the ER stress sensor IRE1α in metabolic regulation and disease. Journal of Biological Chemistry, 2019. 294(49): p. 18726-18741. 102. Hetz, C., et al., The unfolded protein response: integrating stress signals through the stress sensor IRE1α. Physiological reviews, 2011. 91(4): p. 1219-1243. 103. Liu, C.Y. and R.J. Kaufman, The unfolded protein response. Journal of Cell Science, 2003. 116(10): p. 1861-1862. 104. Jheng, J.-R., et al., A novel role of ER stress signal transducer ATF6 in regulating enterovirus A71 viral protein stability. Journal of biomedical science, 2018. 25(1): p. 1-12. 105. Mehlem, A., et al., Imaging of neutral lipids by oil red O for analyzing the metabolic status in health and disease. Nature protocols, 2013. 8(6): p. 1149-1154. 106. Badid, C., et al., Interstitial expression of α‐SMA: an early marker of chronic renal allograft dysfunction. Nephrology Dialysis Transplantation, 2002. 17(11): p. 1993-1998. 107. Gai, Z., et al., Lipid accumulation and chronic kidney disease. Nutrients, 2019. 11(4): 722. 108. You, M., et al., Ethanol induces fatty acid synthesis pathways by activation of sterol regulatory element-binding protein (SREBP). Journal of Biological Chemistry, 2002. 277(32): p. 29342-29347. 109. Varga, T., Z. Czimmerer, and L. Nagy, PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 2011. 1812(8): p. 1007-1022. 110. Lopes, T.G., et al., Markers of renal fibrosis: How do they correlate with podocyte damage in glomerular diseases? PloS one, 2019. 14(6): p. e0217585. 111. Sandoz, P.A., et al., Label free 3D analysis of organelles in living cells by refractive index shows pre-mitotic organelle spinning in mammalian stem cells. bioRxiv, 2018: 407239. 112. Perry, S.W., et al., Mitochondrial membrane potential probes and the proton gradient: a practical usage guide. Biotechniques, 2011. 50(2): p. 98-115. 113. Godárová, A., et al., L-carnitine regulates mRNA expression levels of the carnitine acyltransferases–CPT1A, CPT2, and CRAT. Monatshefte für Chemie/Chemical Monthly, 2005. 136(8): p. 1349-1363. 114. Swigoňová, Z., A.-W. Mohsen, and J. Vockley, Acyl-CoA dehydrogenases: dynamic history of protein family evolution. Journal of molecular evolution, 2009. 69(2): p. 176-193. 115. Acosta-Alvear, D., et al., XBP1 controls diverse cell type-and condition-specific transcriptional regulatory networks. Molecular cell, 2007. 27(1): p. 53-66. 116. Shao, M., et al., Hepatic IRE1α regulates fasting-induced metabolic adaptive programs through the XBP1s–PPARα axis signalling. Nature communications, 2014. 5(1): p. 1-12. 117. Han, J. and R.J. Kaufman, The role of ER stress in lipid metabolism and lipotoxicity. Journal of lipid research, 2016. 57(8): p. 1329-1338. 118. Lee, A.-H., et al., Regulation of hepatic lipogenesis by the transcription factor XBP1. Science, 2008. 320(5882): p. 1492-1496. 119. Ning, J., et al., Constitutive role for IRE1α-XBP1 signaling pathway in the insulin-mediated hepatic lipogenic program. Endocrinology, 2011. 152(6): p. 2247-2255. 120. Fang, D.-l., et al., Endoplasmic reticulum stress leads to lipid accumulation through upregulation of SREBP-1c in normal hepatic and hepatoma cells. Molecular and cellular biochemistry, 2013. 381(1-2): p. 127-137. 121. He, M., et al., Identification and characterization of new long chain acyl-CoA dehydrogenases. Molecular genetics and metabolism, 2011. 102(4): p. 418-429. 122. Jiang, D., et al., Analysis of p53 transactivation domain mutants reveals Acad11 as a metabolic target important for p53 pro-survival function. Cell reports, 2015. 10(7): p. 1096-1109. 123. Contreras, A.V., N. Torres, and A.R. Tovar, PPAR-α as a key nutritional and environmental sensor for metabolic adaptation. Advances in nutrition, 2013. 4(4): p. 439-452. 124. Tahmaz, M., et al., Acute renal failure secondary to fenofibrate monotherapy-induced rhabdomyolysis. Renal failure, 2007. 29(7): p. 927-930. 125. Danis, R., et al., Rhabdomyolysis-induced acute renal failure following fenofibrate therapy: a case report and literature review. Case reports in medicine, 2010: 537818. 126. Ansquer, J.-C., et al., Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). American Journal of Kidney Diseases, 2005. 45(3): p. 485-493. 127. Bhatia, D. and M.E. Choi, The Emerging Role of Mitophagy in Kidney Diseases. Journal of life sciences (Westlake Village, Calif.), 2019. 1(3): p. 13-22. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/18399 | - |
dc.description.abstract | 慢性腎臟病 (chronic kidney disease, CKD)最終可能發展為終末期腎臟衰竭 (end-stage renal disease, ESRD),其具有高盛行率以及高死亡率,並造成龐大的醫療負擔,在現今社會已成為全球迫切關注的公共衛生議題。近年許多的研究證據顯示,在急性腎臟損傷 (acute kidney injury, AKI)後,腎臟功能復原情形較差的病患可能是進展成CKD的潛在族群,因此驅使越來越多的研究著重於急性腎臟損傷至慢性腎臟病的機制探討。臨床上,纖維化為CKD不可逆的組織學表現,其中脂質累積以及脂肪酸β-氧化在腎臟病發展中扮演重要角色,特別是近端腎小管細胞,其對於能量需求極大,並以脂肪酸作為其主要能量來源。先前研究指出,當脂質代謝異常或粒線體功能障礙,都可能導致脂質累積,進而促進纖維化以及腎臟病的發展。根據本實驗室先前的研究成果,透過小鼠單側腎臟缺血再灌流損傷 (unilateral ischemia reperfusion injury, UIRI),模擬急性腎臟損傷後腎臟纖維化進程的研究結果顯示,未折疊蛋白質反應作用因子X-box binding protein 1 (XBP1)的表現量與纖維化呈現負相關,我們進一步發現到UIRI後腎組織脂質累積增加,並伴隨調節脂肪酸合成轉錄因子:sterol regulatory element-binding protein 1 (SREBP-1)上升和調節脂肪酸β-氧化轉錄因子:peroxisome proliferator-activated receptor alpha (PPARα)下降。根據上述結果,本研究假設XBP1對於腎臟脂質累積和脂質代謝中扮演重要角色,首先,我們透過腎小管上皮細胞特異性XBP1基因剃除小鼠(XBP1 cKO)去驗證此推論,發現到在UIRI後XBP1 cKO 小鼠與wild-type 小鼠相比,其脂質累積加劇和SREBP-1, α-SMA表現顯著上升以及PPARα表現顯著下降的現象。此外,我們也證實在UIRI後處理fenofibrate的小鼠能夠維持PPARα表現,並能回復XBP1的表現以及減輕纖維化和脂質累積。接著在in vitro模式,我們透過人類腎臟近端腎小管上皮細胞 (HK-2)去探討XBP1缺乏下對脂質累積的影響,透過添加棕櫚酸 (Pa-BSA)以加強脂質累積的現象,並藉由Oil Red O染色觀察,發現到XBP1缺失下會造成脂質累積上升,也透過活細胞成像顯微鏡觀察到XBP1缺失下油滴數量增加。脂質代謝異常下會造成脂質累積,我們進一步觀察XBP1缺乏對於脂肪酸合成、脂肪酸攝取和脂肪酸β-氧化的影響,結果指出在XBP1缺乏下SREBP-1以及脂肪酸攝取膜蛋白:cluster of differentiation 36 (CD36) 表現顯著上升,而PPARα表現顯著下降。由於粒線體脂肪酸β-氧化主要由PPARα調控,因此粒線體功能障礙也是造成脂質累積的因素之一,我們接著去探討XBP1對於粒線體功能的影響,則結果發現到XBP1缺乏下,粒線體功能受到顯著的損害,我們進一步分析多種PPARα標的基因,發現到其中carnitine palmitoyltransferase-2 (CPT2) 表現上升和acyl-CoA dehydrogenase family member 11 (Acad11)表現下降。在先前文獻已指出PPARα在肝臟細胞中受到XBP1s調控,我們進一步去證明XBP1在腎小管細胞中調控PPARα的機制,透過大量表現XBP1s和XBP1u,發現到PPARα表現上升,進而透過Luciferase assay發現XBP1s會和PPARα promoter相互作用。本研究發現在腎小管上皮細胞中,XBP1可能作為調控脂質代謝以及粒線體功能的重要角色,缺乏XBP1下會造成脂質代謝異常及線粒體功能障礙,並加劇脂質累積,最後促使纖維化的進展。 | zh_TW |
dc.description.abstract | Chronic kidney disease (CKD) progression to end-stage renal disease (ESRD), which causes the high prevalence and mortality and huge economic burden. Nowadays, it has turned into the public health issues of global concern. In recent years, there is a lot of evidence that patients with poor ability to recover after acute kidney injury (AKI) may be the potential group of CKD. Thus, prompting more and more studies focused on mechanism investigation of AKI to CKD transition. Clinically, fibrosis is an irreversible histological manifestation of CKD. However, the lipid accumulation and fatty acid β-oxidation play a crucial role in the development of renal disease, which is especially for proximal tubular cells (PTCs). Owing to the high-energy demand, and they use fatty acid as the major energy source. Previous studies have showed that the aberrant lipid metabolism or mitochondrial dysfunction cause the lipid accumulation, which further promoted the progression of fibrosis and renal disease. In our previous study, we mimicked the process of renal fibrosis after acute kidney injury using the mice model of unilateral ischemia reperfusion injury (UIRI). We observed the expression of the unfolded protein response effector, X-box binding protein 1 (XBP1) was negatively correlated with the degree of post-AKI fibrosis. In addition, we further found the gradual increase of lipid accumulation in renal tissue after UIRI, and accompanied with the increase of fatty acid synthesis regulated transcription factor-sterol regulatory element-binding protein 1 (SREBP-1) and the decrease of fatty acid β-oxidation regulated transcription factor-peroxisome proliferator-activated receptor alpha (PPARα). On the basis of above results, this study hypothesized that XBP1 may play an important role in lipid accumulation and lipid metabolism of renal. Then, we examined this suppose using renal tubular epithelial specific XBP1 knockout (XBP1 cKO) mice. We observed the lipid accumulation was aggravated, the expression of SREBP-1 was significantly increased, and the expression of PPARα was significantly decreased in XBP1 cKO mice after UIRI. Moreover, we confirmed that fenofibrate-treated mice maintain the expression of PPARα after UIRI. Simultaneously, the expression of XBP1 were recovered, and ameliorated the fibrosis and lipid accumulation. In the in vitro model, we first investigated the impact of XBP1 deficiency on the lipid accumulation using human renal proximal tubule epithelial cells (HK-2). We added the palmitate (Pa-BSA) to enhance the lipid accumulation and observed with Oil Red O staining. The data showed XBP1 deficiency promoted the lipid accumulation. Also, we observed the XBP1 deficiency increased the number of lipid droplets by using Nanolive 3D cell explorer. We further examined the impact of XBP1 deficiency on fatty acid synthesis, fatty acid uptake and fatty acid β-oxidation. The results showed that the expression of SREBP-1 and fatty acid uptake membrane protein—cluster of differentiation 36 (CD36) were significantly increased, whereas the expression of PPARα was significantly decreased in the XBP1 deficiency. Moreover, the fatty acid β-oxidation is mainly regulated by PPARα and plays a role in mitochondria. Therefore, the mitochondrial dysfunction is also one of the cause that result in the lipid accumulation. We further explored the effect of XBP1 on mitochondrial function. The data showed that XBP1 deficiency was markedly inhibited the mitochondrial function. We further analyzed a variety of PPARα target genes. The XBP1 deficiency were up-regulated the expression of carnitine palmitoyltransferase-2 (CPT2), whereas down-regulated the expression of acyl-CoA dehydrogenase family member 11 (Acad11). The previous study have indicated that PPARα is regulated by XBP1s in liver cells. Thus, we further elucidated the potential mechanisms of XBP1-regulated PPARα. Through the overexpression of XBP1s and XBP1u, we found that the expression of PPARα was increased. We further used the luciferase assay to find that XBP1s could interact with PPARα promoter. To summary our results, XBP1 play an important role in regulating lipid metabolism and mitochondrial function in PTCs. The lack of XBP1 will cause aberrant lipid metabolism and mitochondrial dysfunction, resulting in lipid accumulation, and eventually promote the progression of fibrosis. | en |
dc.description.provenance | Made available in DSpace on 2021-06-08T01:03:17Z (GMT). No. of bitstreams: 1 U0001-1208202016390800.pdf: 3417834 bytes, checksum: 3a26d06a40ad4c3a2459628855c12720 (MD5) Previous issue date: 2020 | en |
dc.description.tableofcontents | 口試委員會審定書 I 目錄 II 誌謝 IV 摘要 VI Abstract VIII Abbreviation Summary XI Part I: Introduction 1 1.1 Kidneys 1 1.2 Acute kidney injury 1 1.3 Chronic kidney disease 2 1.4 AKI to CKD transition 3 1.5 Mitochondrial pathology of the transition from AKI to CKD 4 1.5.1 Mitochondrial dynamics 5 1.5.2 Mitochondrial biogenesis 6 1.5.3 Mitophagy 7 1.6 Renal disease and lipotoxicity 8 1.6.1 The fatty acid synthesis in renal disease 9 1.6.2 The fatty acid uptake in renal disease 10 1.6.3 The fatty acid β-oxidation in renal disease 12 1.7 ER stress and unfolded protein response pathway 15 1.8 The correspond evidences with ER stress, lipotoxicity, and ischemia-reperfusion injury 19 Part II: Aims 20 Part III: Materials and Methods 21 3.1 Cell culture 21 3.2 Animal studies 22 3.3 In vitro knockdown or overexpression of XBP1 23 3.4 Preparation of bovine serum albumin-conjugated palmitate 24 3.5 Oil Red O staining 25 3.6 Seahorse assay 26 3.7 Immunoblot analysis 26 3.8 RNA extraction and gel electrophoresis 28 3.9 Quantitative real-time polymerase chain reaction (qRT-PCR) 29 3.10 Mitochondrial membrane potential (MMP) measurement 30 3.11 Live cell 3D holotomographic microscopy 31 3.12 Trypan blue staining assay 31 3.13 Dual luciferase reporter assay 32 3.14 Statistical analysis 33 Part IV: Results 34 4.1 The lipid gradually accumulates in the PTCs in the transition of AKI to CKD with the aberrant lipid metabolism 34 4.2 Conditional XBP1 knockout mice aggravated lipid accumulation, fibrosis and caused the aberrant lipid metabolism after UIRI 35 4.3 Fenofibrate-treated recovers the expression of XBP1 and ameliorates the fibrosis and lipid accumulation after UIRI 37 4.4 XBP1 knockdown causes the rise of lipid accumulation and lipid droplets 39 4.5 XBP1 knockdown causes the aberrant lipid metabolism through regulating the gene of fatty acid uptake, synthesis and oxidation 41 4.6 XBP1 knockdown causes the impairment of mitochondria function by down-regulating Acad11 42 4.7 To elucidate the potential mechanisms of XBP1-regulated PPARα 45 Part V: Discussion 47 Part VI: Conclusion 53 Part VII: Future perspectives 54 Part VIII: References 55 Part IX: Figures 73 Figure 1 73 Figure 2 75 Figure 3 76 Figure 4 77 Figure 5 81 Figure 6 85 Figure 7 87 Figure 8 89 Figure 9 91 Figure 10 92 Figure 11 93 Figure 12 95 Part X: Supplementary figures 96 Supplementary figure 1 96 Supplementary figure 2 97 Supplementary figure 3 99 | |
dc.language.iso | en | |
dc.title | 近端腎小管XBP1缺失加劇缺血/再灌流誘導急性腎損傷到慢性腎臟病脂質累積 | zh_TW |
dc.title | Renal proximal tubule XBP1 deficiency aggravates lipid accumulation in ischemia/reperfusion-induced AKI-CKD transition | en |
dc.type | Thesis | |
dc.date.schoolyear | 108-2 | |
dc.description.degree | 碩士 | |
dc.contributor.author-orcid | 8834-7777-1245-8899 | |
dc.contributor.advisor-orcid | 姜至剛(8834-0001-4401-9821) | |
dc.contributor.oralexamcommittee | 劉興華(Shing-Hwa Liu),許美鈴(Meei-Ling Sheu),吳鎮天(Cheng-Tien Wu) | |
dc.contributor.oralexamcommittee-orcid | 劉興華(8837-0001-4401-9821),許美鈴(8833-0001-4401-9821),吳鎮天(8887-0001-4401-9821) | |
dc.subject.keyword | 慢性腎臟病,腎小管細胞,脂質累積,粒線體,未折疊蛋白反應, | zh_TW |
dc.subject.keyword | Chronic kidney disease,Proximal tubular cells,Lipid accumulation,Mitochondria,Unfolded protein response, | en |
dc.relation.page | 100 | |
dc.identifier.doi | 10.6342/NTU202003124 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2020-08-19 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 毒理學研究所 | zh_TW |
顯示於系所單位: | 毒理學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
U0001-1208202016390800.pdf 目前未授權公開取用 | 3.34 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。